Takeda Pharmaceutical (TAK) Cash & Equivalents: 2018-2025

  • Takeda Pharmaceutical's Cash & Equivalents fell 18.29% to $2.5 billion in Q1 2025 from the same period last year, while for Mar 2025 it was $2.5 billion, marking a year-over-year decrease of 18.29%. This contributed to the annual value of $2.5 billion for FY2025, which is 20.36% down from last year.
  • Takeda Pharmaceutical's Cash & Equivalents amounted to $2.5 billion in Q1 2025, which was down 18.29% from $3.1 billion recorded in Q1 2024.
  • Over the past 5 years, Takeda Pharmaceutical's Cash & Equivalents peaked at $9.1 billion during Q1 2021, and registered a low of $2.5 billion during Q1 2025.
  • Over the past 3 years, Takeda Pharmaceutical's median Cash & Equivalents value was $3.1 billion (recorded in 2024), while the average stood at $3.2 billion.
  • In the last 5 years, Takeda Pharmaceutical's Cash & Equivalents surged by 55.88% in 2021 and then slumped by 44.83% in 2023.
  • Takeda Pharmaceutical's Cash & Equivalents (Quarterly) stood at $9.1 billion in 2021, then decreased by 19.90% to $7.3 billion in 2022, then slumped by 44.83% to $4.0 billion in 2023, then decreased by 23.41% to $3.1 billion in 2024, then declined by 18.29% to $2.5 billion in 2025.
  • Its Cash & Equivalents was $2.5 billion in Q1 2025, compared to $3.1 billion in Q1 2024 and $4.0 billion in Q1 2023.